Mayo Clinic
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitors. It works by blocking the action of a substance that signals tumor cells to multiply. This helps stop or slow the spread of tumor cells. Giving retifanlimab with or without DFMO mat be safe, tolerable and/or effective in treating patients with progressive high grade glioma.
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of high-grade glioma, including any of the following: * Glioblastoma, IDH-wild type (WT) * Grade 3 or 4 IDH1/2 mutant astrocytoma or * Grade 3 oligodendroglioma * Any prior grade 2 astrocytoma or oligodendroglioma that is suspected to have recurred at a higher grade * Other high-grade glioma * Plan for surgical resection as part of routine clinical care * Radiographic disease progression, with or without tissue confirmation * Measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 and Karno…
Undergo blood and CSF collection
Given PO
Undergo lumbar puncture
Undergo MRI
Given IV
Undergo resection surgery
Arctuva estimate
Verify or correct the compensation shown for this listing.